Jubilant Pharmova Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

The Jubilant Pharmova stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Jubilant Pharmova share price prediction as one data point and not as a guarantee of future performance.

This article reviews every dimension of the Jubilant Pharmova stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

What Analysts Predict for Jubilant Pharmova Stock in 2026

Analyst consensus on the Jubilant Pharmova stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and ICICI Securities. All figures are sourced from publicly available research and should be verified before publishing.

Brokerage	Rating	Jubilant Pharmova Stock Prediction (Rs)	Updated
JM Financial	Buy	Rs 1150	2026
ICICI Securities	Buy	Rs 1080	2026
Analyst Consensus	—	Rs 1115	2026

The analyst target range for Jubilant Pharmova reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Jubilant Pharmova stock forecast from the current price of Rs 987 may or may not be realised by end of 2026.

Jubilant Pharmova Company Overview

Jubilant Pharmova is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Jubilant Pharmova stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.

Metric	Value
NSE Ticker	JUBLPHARMA
Sector	Pharmaceuticals and Healthcare
CMP	Rs 987 (2026)
52 Week High	Rs 1,250
52 Week Low	Rs 784
Market Cap	Rs 15,733 Cr
P/E Ratio	502
Jubilant Pharmova Stock Prediction Consensus (12M)	Rs 1115

Jubilant Pharmova Stock Prediction by Time Horizon

Analysts split the Jubilant Pharmova share price prediction across time frames as near-term drivers differ materially from the long-term view.

Short-Term Jubilant Pharmova Stock Prediction

The near-term Jubilant Pharmova stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 987 are being watched closely. A short-term Jubilant Pharmova share price prediction carries the most uncertainty of any time horizon.

12-Month Jubilant Pharmova Stock Prediction

JM Financial targets Rs 1150 (Buy) and ICICI Securities targets Rs 1080 (Buy). Most desks refresh their Jubilant Pharmova stock forecast within two to four weeks of each quarterly earnings print. The Jubilant Pharmova share price prediction should be verified against the most recent analyst reports.

Long-Term Jubilant Pharmova Stock Prediction

The long-term outlook for Jubilant Pharmova is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. Long-term price targets carry the most uncertainty and should be treated as directional guidance only.

Jubilant Pharmova Stock Forecast: Key Factors

The following four factors appear consistently in analyst research on Jubilant Pharmova and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Jubilant Pharmova stock forecast. USFDA approval timelines and price erosion rates directly affect the Jubilant Pharmova share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Jubilant Pharmova stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Jubilant Pharmova share price prediction. New product approvals are cited as catalysts for the Jubilant Pharmova stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Jubilant Pharmova stock forecast. Margin recovery strengthens the Jubilant Pharmova share price prediction from most research desks.

Jubilant Pharmova Stock Prediction: Bull and Bear Scenarios

Scenario	Jubilant Pharmova Stock Prediction	Key Conditions
Bull Case	Rs 1150	Strong execution, margin improvement, favourable macro and sector re-rating
Base Case	Rs 1115	Steady performance, gradual recovery, margins hold, growth on track
Bear Case	Rs 784	Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Jubilant Pharmova stock forecast of Rs 1150 assumes most positive variables converge. The base case of Rs 1115 is the analyst consensus and may or may not be achieved.

How Analysts Are Reading the Jubilant Pharmova Stock Story

Analyst reviews of the Jubilant Pharmova share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the analyst consensus for Jubilant Pharmova is built on real business strengths set against real risks.

Key Risks to the Jubilant Pharmova Stock Prediction

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Jubilant Pharmova stock prediction. A facility closure would force an immediate sharp revision to the Jubilant Pharmova share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Jubilant Pharmova stock forecast. Aggressive price erosion pushes the Jubilant Pharmova share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Jubilant Pharmova stock prediction. The Jubilant Pharmova share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Jubilant Pharmova stock forecast. Currency risk is embedded in conservative Jubilant Pharmova share price prediction models.

How to Monitor the Jubilant Pharmova Stock Forecast

Track the Jubilant Pharmova share price prediction consensus quarterly. After every earnings release, most brokerages revise their Jubilant Pharmova stock forecast within two weeks. Comparing the revised analyst target to the previous estimate tells you whether sentiment on Jubilant Pharmova is improving or deteriorating.

Compare the current price of Rs 987 with the analyst target range of Rs 1150 to Rs 1080. A wide target band reflects genuine uncertainty on Jubilant Pharmova, so position size should reflect that range rather than the midpoint alone.

Review the Jubilant Pharmova share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.

Check Live Jubilant Pharmova Fundamentals on the Univest Screener

Conclusion

The Jubilant Pharmova stock prediction for 2026 reflects the analyst community’s assessment of Jubilant Pharmova’s competitive position, earnings trajectory and macro environment. JM Financial holds a Buy stance with a target of Rs 1150 while ICICI Securities has a Buy rating with a target of Rs 1080, giving an analyst consensus of Rs 1115.

The Jubilant Pharmova stock forecast is set against near-term risks that make the Jubilant Pharmova share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking how the Jubilant Pharmova share price target changes over time is more valuable than relying on any single estimate.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Download the Univest iOS App or Univest Android App to track live analyst targets, price movements and research updates for Jubilant Pharmova in real time.

Frequently Asked Questions on Jubilant Pharmova Stock Prediction 2026

What is the Jubilant Pharmova stock prediction for 2026?

Ans. The Jubilant Pharmova stock prediction for 2026 is based on analyst consensus from JM Financial and ICICI Securities. The consensus target is Rs 1115. All estimates may or may not be achieved.

Is the Jubilant Pharmova stock prediction bullish or bearish?

Ans. JM Financial has a Buy rating with target Rs 1150. ICICI Securities has a Buy rating with target Rs 1080. The Jubilant Pharmova stock forecast reflects genuine analyst diversity of opinion.

What is the Jubilant Pharmova share price prediction based on fundamentals?

Ans. The Jubilant Pharmova share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Jubilant Pharmova closely cite these as the primary drivers of the 2026 outlook.

What is the long-term Jubilant Pharmova stock prediction?

Ans. The long-term outlook assumes Jubilant Pharmova sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 1115 is the nearest reliable anchor point.

What are the key risks to the Jubilant Pharmova stock prediction?

Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every analyst estimate for Jubilant Pharmova should be read alongside its risk assumptions.

What does the Jubilant Pharmova stock forecast say for 2026?

Ans. JM Financial: Buy target Rs 1150. ICICI Securities: Buy target Rs 1080. These Jubilant Pharmova share price prediction estimates may or may not prove accurate.

Where can I track the latest Jubilant Pharmova stock prediction?

Ans. Track the latest analyst targets and price movements for Jubilant Pharmova on the NSE and BSE websites and on the Univest app and screener for live data.